GE Achieves Record Transmission of Power on a Super Energy Highway in India
14.11.2019 14:59:00 EET | Business Wire | Press release
GE’s Grid Solutions business (NYSE:GE) announced today a new milestone in its Champa-Kurukshetra ultra-high-voltage direct current (UHVDC) project in India with the 1,305-km link now capable of transmitting 4,500 MW of electricity. This follows the recent successful energization of the third of four poles planned for the ±800kV UHVDC transmission line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005360/en/
Inside the Valve Hall of the Champa-Kurukshetra HVDC Converter Station, image courtesy of GE (Photo: Business Wire)
A special feature of the Champa project is the use of an overhead line with dedicated metallic return, which uses a neutral conductor as a part of the DC circuit. GE is the first company in the world to demonstrate this technology with this project and is therefore providing additional value to the customer by eliminating the typical technical and environmental issues associated with the traditional electrode solution.
The transmission line is a crucial component of the Indian government’s electricity-for-all initiative and will help provide reliable electricity for millions of people living in the states of Punjab, Haryana, Delhi, Uttar Pradesh and surrounding areas. The project is being executed by GE T&D India Limited, the listed entity of GE’s Grid Solutions business in India.
New government initiatives and robust private-sector investments have reversed India’s longstanding power deficit. With the growing renewable energy market, the nation now boasts an installed capacity of over 360 gigawatts (GW), making it the third-largest electricity producer in the world. However, to meet the government’s vision of power-to-all and to ensure last mile connectivity, continuous development of a robust transmission network is vital for the country.
Power Grid Corporation of India Ltd (POWERGRID), India’s largest state-owned transmission company, is helping address this issue by connecting the power deficit northern Indian region with power surplus regions of eastern India using GE’s UHVDC technology.
“Thanks to this latest milestone in the GE Champa-Kurukshetra project, India is now transmitting more electricity over this link than any other DC link in India, helping to resolve the supply shortfalls in the north. This project also includes an integration where two separately designed bi-poles are running in parallel operation over the same DC transmission line, a design feature only seen on two other HVDC projects in the world, both of which GE was involved with, a great compliment to our legacy and current HVDC controls capability. On behalf of everyone at GE’s Grid Solutions, I would like to thank our teams in India and our UK HVDC center of excellence for this remarkable feat,” said Rajendra Iyer, head of Grid Integrated Solutions at GE’s Grid Solutions. The Grid Integration Solutions division, comprised of High Voltage Direct Current (HVDC) and FACTS technologies, designs and integrates transmission solutions that help meet the world’s ever-evolving power needs.
The Champa-Kurukshetra project transmits electricity from power generating plants located across Chhattisgarh, a state in eastern region of India, to a GE-built rectifier station in Champa, where it is converted from alternating current (AC) to direct current (DC). The electricity is transported in bulk across the UHVDC line and is then converted back to AC by a GE inverter station in Kurukshetra, Haryana. From there, power is transported to the surrounding rural states who are in need of reliable and consistent electrical power. DC technology efficiently moves electricity over long distances which lowers transmission costs and losses. Additionally, it is a more environment-friendly technology because it requires fewer overhead lines to deliver the same amount of power as a high-voltage AC system.
Phase 1 of the project, completed in 2017, provided 3,000 MW of transmission capacity. GE’s recent energization of Pole 3 added another 1,500 MW of transmission capacity, marking a key benchmark towards the completion of Phase 2. Once Pole 4 is commissioned, the entire system will transmit 6,000 MW of electricity at 800kV - making the project one of the largest generation-to-consumption transmission systems in the world.
Notes to Editors:
About GE T&D India Limited:
GE T&D is the listed entity of GE’s Grid Solutions business in India. With over 100 years of presence in India, GE T&D India is a leading player in the Power Transmission & Distribution business with a product portfolio ranging from Medium Voltage to Ultra High Voltage (1,200 kilovolt) for Power Generation, Transmission and Distribution, Industry and Infrastructure markets.
GE T&D India has a significant presence in all stages of the power supply chain and offers a wide range of products that include Power Transformers, Circuit Breakers, Gas Insulated Switchgears, Instrument Transformers, Substation Automation Equipment. Digital Software Solutions, Turnkey Solutions for Substation Engineering & Construction, Flexible AC Transmission Systems, High Voltage DC & Services suite of offerings. With six manufacturing sites, GE T&D India is future ready to meet the growing demands for equipment and services. GE is focused towards on introducing Green and Digital Solutions aimed towards making the Indian Grid smarter and more environmentally-friendly.
About GE’s Grid Solutions:
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. For more about GE Renewable Energy’s Grid Solutions business, visit www.gegridsolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005360/en/
Contact information
For media queries, please contact:
Anshul Madaan
Communications Leader
GE Grid Solutions – South Asia
anshul.madaan@ge.com
Allison J. Cohen
GE Renewable Energy, Grid Solutions business
External Communications Manager
+972-(0)54-7299742
allison.j.cohen@ge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom